Answers are grounded in this paper and cite their sources.
Juvenile myasthenia gravis (JMG) is a rare disease diagnosed based on fluctuating fatigable skeletal muscle weakness and electrophysiological tests. We herein report an atypical presentation of JMG. A 12-year-old boy presented with lagophthalmos, swallowing difficulty and voice change without diurnal variation. A possibility of Guillain-Barré syndrome (GBS) was considered. Initially, he improved with intravenous immunoglobulin (IVIg) with mild residual facial weakness. He was admitted with relapse requiring mechanical ventilation. Considering this relapsing course, neostigmine was administered, which showed improvement in weakness. JMG was confirmed with repetitive nerve stimulation (RNS) test and serology. After he was started on oral steroids and pyridostigmine, he had refractory course requiring IVIg twice, addition of azathioprine and, later, rituximab infusions. He is on follow-up with no residual bulbar weakness. The incomplete initial presentation of JMG can mimic GBS. Rituximab must be considered early in patients with refractory JMG.
No takes yet. Share an insight, caveat, or question.
Sreenivasan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: